Santarus, Inc. (NASDAQ:SNTS)
CAPS Rating:
A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.
RSS Headlines
Fool UK
Recs
Incrementally rising market share in a multi-billion $ market. An effective product with proven advantages over the competition and a brand new distribution deal with Schering-Plough. This is a potential buy-out candidate.